Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.174.62 ]

🍽️ bufexamac,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Dermatological Conditions: Bufexamac is commonly used to treat various dermatological conditions, including:

    • Eczema: It helps reduce inflammation, itching, and redness associated with eczematous skin conditions.
    • Contact Dermatitis: Bufexamac can alleviate symptoms of contact dermatitis, such as itching, burning, and swelling, caused by contact with irritants or allergens.
    • Allergic Skin Reactions: It may be used to relieve symptoms of allergic skin reactions, including hives (urticaria) and allergic dermatitis.
  2. Anti-inflammatory Action: Bufexamac exerts its therapeutic effects by inhibiting the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. By reducing inflammation in the skin, it helps alleviate symptoms of various dermatological conditions.

  3. Analgesic Effect: In addition to its anti-inflammatory properties, bufexamac has mild analgesic (pain-relieving) effects. It can help alleviate pain and discomfort associated with inflammatory skin conditions, providing symptomatic relief to patients.

  4. Topical Formulation: Bufexamac is typically available in topical formulations, such as creams, ointments, or gels, for external application to the affected skin area. Topical application allows for localized treatment of skin inflammation and reduces systemic exposure to the medication.

  5. Mild Side Effects: Common side effects associated with bufexamac use may include skin irritation, burning, stinging, or itching at the site of application. These side effects are usually mild and transient, and they often resolve with continued use or upon discontinuation of the medication.

  6. Allergic Reactions: Although rare, some individuals may experience allergic reactions to bufexamac, including severe skin irritation, rash, or swelling. Patients should discontinue use and seek medical attention if they experience signs of an allergic reaction.

  7. Contraindications: Bufexamac should not be used in individuals with known hypersensitivity to the drug or its components. It is contraindicated in patients with open wounds, broken skin, or infected skin lesions, as it may increase the risk of systemic absorption and adverse effects.

  8. Pregnancy and Lactation: The safety of bufexamac use during pregnancy and breastfeeding has not been well established. Pregnant or lactating women should consult with a healthcare professional before using bufexamac to weigh the potential benefits against the risks.

  9. Drug Interactions: Bufexamac is primarily used topically, which minimizes the risk of systemic drug interactions. However, patients should inform their healthcare providers about all medications, including over-the-counter drugs and supplements, to avoid potential interactions.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of bufexamac,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by bufexamac,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Eggerthella genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Escherichia genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Coprococcus comes species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Lachnospira eligens species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Roseburia hominis species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Lacrimispora saccharolytica species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of bufexamac,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0 0
ADHD 0.3 0.6 -1
Age-Related Macular Degeneration and Glaucoma 0 0
Allergic Rhinitis (Hay Fever) 0.2 0.2
Allergies 1 1
Allergy to milk products 0.5 0.2 1.5
Alzheimer's disease 1 0.8 0.25
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.5 0.4 0.25
Ankylosing spondylitis 1.2 0.3 3
Anorexia Nervosa 0.1 -0.1
Antiphospholipid syndrome (APS) 0.6 0 0
Asthma 1 0.1 9
Atherosclerosis 0.2 0 0
Atrial fibrillation 0.8 0.2 3
Autism 2.2 1.3 0.69
Barrett esophagus cancer 0.7 0.1 6
benign prostatic hyperplasia 0.2 0.2
Bipolar Disorder 0.2 1.1 -4.5
Brain Trauma 0.1 -0.1
Carcinoma 0.9 0 0
Celiac Disease 1 0.5 1
Cerebral Palsy 0.6 0.1 5
Chronic Fatigue Syndrome 2.5 0.9 1.78
Chronic Kidney Disease 0.7 0.2 2.5
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 1.1 0.2 4.5
Chronic Urticaria (Hives) 1.2 0 0
Coagulation / Micro clot triggering bacteria 0.8 0.2 3
Colorectal Cancer 1.7 1.7
Constipation 0.3 0 0
Coronary artery disease 0.5 -0.5
COVID-19 3 1.3 1.31
Crohn's Disease 2.5 0.7 2.57
cystic fibrosis 0.7 0.1 6
deep vein thrombosis 0.7 0.2 2.5
Depression 3.2 1.8 0.78
Dermatomyositis 0.1 0.1
Eczema 0.6 0.4 0.5
Endometriosis 0.9 0.5 0.8
Eosinophilic Esophagitis 0.2 0.4 -1
Epilepsy 0.6 0 0
Fibromyalgia 0 0.2 0
Functional constipation / chronic idiopathic constipation 0.8 0.2 3
gallstone disease (gsd) 0.6 0.3 1
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.7 0.1 6
Generalized anxiety disorder 0.9 0.1 8
Glioblastoma 0.1 -0.1
Gout 0.1 -0.1
Graves' disease 0 0 0
Halitosis 0.7 0.1 6
Hashimoto's thyroiditis 0.1 0 0
Hidradenitis Suppurativa 0.4 0.4 0
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.6 0.6
hyperglycemia 0.2 0 0
hypersomnia 0 0
hypertension (High Blood Pressure 0.4 0.4 0
Hypothyroidism 0.6 -0.6
Hypoxia 0 0
IgA nephropathy (IgAN) 0.2 -0.2
Inflammatory Bowel Disease 1.6 0.3 4.33
Insomnia 0.2 0.1 1
Intelligence 0.1 0.1
Intracranial aneurysms 0 0
Irritable Bowel Syndrome 1.2 0.6 1
Liver Cirrhosis 1.2 0.7 0.71
Long COVID 1.9 0.7 1.71
Low bone mineral density 0.2 -0.2
Lung Cancer 0.3 0.3
ME/CFS with IBS 0.1 0.2 -1
ME/CFS without IBS 1.8 0 0
Metabolic Syndrome 1.8 0.6 2
Mood Disorders 4.1 2.3 0.78
multiple chemical sensitivity [MCS] 0.8 0.8
Multiple Sclerosis 2.1 0.4 4.25
Multiple system atrophy (MSA) 0.1 0.1
Neuropathy (all types) 0.1 0.2 -1
neuropsychiatric disorders (PANDAS, PANS) 0.4 0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.4 0.2 1
Obesity 0.6 1.3 -1.17
obsessive-compulsive disorder 1.4 0.1 13
Osteoarthritis 0.4 0.4
Osteoporosis 1.2 0 0
pancreatic cancer 0.1 0.1
Parkinson's Disease 1.2 1.3 -0.08
Polycystic ovary syndrome 0.2 0 0
Postural orthostatic tachycardia syndrome 0.1 -0.1
Psoriasis 1 0.2 4
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.6 0.8 1
Rosacea 0 0
Schizophrenia 1.6 0.1 15
scoliosis 0.1 0.2 -1
Sjögren syndrome 1.6 0 0
Sleep Apnea 0.3 0.7 -1.33
Small Intestinal Bacterial Overgrowth (SIBO) 0.8 0.8
Stress / posttraumatic stress disorder 0.7 1.1 -0.57
Systemic Lupus Erythematosus 1.7 0.1 16
Tourette syndrome 0 0
Type 1 Diabetes 0.8 0.3 1.67
Type 2 Diabetes 1.8 1 0.8
Ulcerative colitis 1.1 0.2 4.5
Unhealthy Ageing 1.9 0.1 18

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. [35.174.62 ]